Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south-eastern Brazil.
Adolescent
Adult
Aged
Aged, 80 and over
Animals
Antifungal Agents
/ pharmacology
Brazil
Child
Cryptococcosis
/ microbiology
Cryptococcus gattii
/ drug effects
Cryptococcus neoformans
/ drug effects
Drug Resistance, Fungal
Female
Humans
Larva
Male
Microbial Sensitivity Tests
Middle Aged
Molecular Typing
Moths
Mycological Typing Techniques
Polymorphism, Restriction Fragment Length
Retrospective Studies
Virulence
Young Adult
Galleria mellonella
Cryptococcus neoformans/C. gattii species complex
clinical isolates
epidemiological cut-off value
molecular type
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
22
06
2020
revised:
17
08
2020
accepted:
19
08
2020
pubmed:
2
9
2020
medline:
13
7
2021
entrez:
2
9
2020
Statut:
ppublish
Résumé
Cryptococcus neoformans/ Cryptococcus gattii species complex is composed of encapsulated yeast species that are causative agents of cryptococcosis. The characterisation of pathogenic Cryptococcus species provides useful data for epidemiological studies as well as the clinical diagnosis and treatment of patients. This study aimed to characterise the epidemiology, antifungal susceptibility and virulence of 72 clinical strains isolated from cryptococcosis cases between 2012 and 2017 in a tertiary reference hospital in south-eastern Brazil. Species and molecular types were molecularly assessed by PCR and PCR-restriction fragment length polymorphism (RFLP) of the URA5 gene. Antifungal susceptibility testing was performed according to the CLSI protocols. The virulence was studied in a Galleria mellonella infection model. The most frequently isolated strain was C. neoformans molecular type VNI (61/72; 84.7%), although C. neoformans molecular type VNII (3/72; 4.2%) was also isolated. Additionally, C. deuterogattii molecular type VGII (8/72; 11.1%) was present, but most frequently from non-HIV-infected patients. Non-wild-type phenotype to the antifungals was observed in 26.4% (19/72) of the C. neoformans and C. deuterogattii clinical isolates, and the latter demonstrated higher MIC to fluconazole and itraconazole than C. neoformans clinical isolates. Finally, the virulence of C. neoformans and C. deuterogattii clinical isolates was diverse in G mellonella larvae and uncorrelated with the virulence factors of melanin and capsule. The assessment of the spread of cryptococcal species and molecular types as well as the pattern of corresponding antifungal susceptibility and virulence aids in surveil the emergence of resistant strains, ensuring more accurate management of the cryptococcal infection.
Sections du résumé
BACKGROUND
BACKGROUND
Cryptococcus neoformans/ Cryptococcus gattii species complex is composed of encapsulated yeast species that are causative agents of cryptococcosis. The characterisation of pathogenic Cryptococcus species provides useful data for epidemiological studies as well as the clinical diagnosis and treatment of patients.
OBJECTIVES
OBJECTIVE
This study aimed to characterise the epidemiology, antifungal susceptibility and virulence of 72 clinical strains isolated from cryptococcosis cases between 2012 and 2017 in a tertiary reference hospital in south-eastern Brazil.
METHODS
METHODS
Species and molecular types were molecularly assessed by PCR and PCR-restriction fragment length polymorphism (RFLP) of the URA5 gene. Antifungal susceptibility testing was performed according to the CLSI protocols. The virulence was studied in a Galleria mellonella infection model.
RESULTS
RESULTS
The most frequently isolated strain was C. neoformans molecular type VNI (61/72; 84.7%), although C. neoformans molecular type VNII (3/72; 4.2%) was also isolated. Additionally, C. deuterogattii molecular type VGII (8/72; 11.1%) was present, but most frequently from non-HIV-infected patients. Non-wild-type phenotype to the antifungals was observed in 26.4% (19/72) of the C. neoformans and C. deuterogattii clinical isolates, and the latter demonstrated higher MIC to fluconazole and itraconazole than C. neoformans clinical isolates. Finally, the virulence of C. neoformans and C. deuterogattii clinical isolates was diverse in G mellonella larvae and uncorrelated with the virulence factors of melanin and capsule.
CONCLUSIONS
CONCLUSIONS
The assessment of the spread of cryptococcal species and molecular types as well as the pattern of corresponding antifungal susceptibility and virulence aids in surveil the emergence of resistant strains, ensuring more accurate management of the cryptococcal infection.
Substances chimiques
Antifungal Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1341-1351Subventions
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : 2017/25300-8
Organisme : Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
ID : Scholarship for Patricia Helena Grizante Barião 0
Informations de copyright
© 2020 Wiley-VCH GmbH.
Références
Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases Society of America. Clin Infect Dis. 2010;50(3):291-322.
Aguiar PADF, Pedroso RDS, Borges AS, Moreira TA, Araújo LB, Röder DVDB. The epidemiology of cryptococcosis and the characterization of Cryptococcus neoformans isolated in a Brazilian University Hospital. Rev Inst Med Trop Sao Paulo. 2017;59:13.
Sorrell TC, Chen SC, Phillips P, Marr KA. Clinical Perspectives on Cryptococcus neoformans and Cryptococcus gattii: Implications for Diagnosis and Management. In Heitman J, Kozel TR, Kwon-Chung KI, Perfect JR, Casadevall A, eds. Cryptococcus: From Human Pathogen to Model Yeast. ASM Press; 2011:595-606.
Lin KH, Chen C-M, Chen T-L, Kuo S-C, Kao C-C, Jeng Y-C. Mao-Wang Ho. Diabetes mellitus is associated with acquisition and increased mortality in HIV-uninfected patients with cryptococcosis: A population-based study. J Infect. 2016;72(5):608-614.
Firacative C, Lizarazo J, Illnait-Zaragozí MT, Castañeda E.The status of cryptococcosis in Latin America. Memórias do Instituto Oswaldo Cruz. 2018;113(7):e170554. Epub April 05, 2018.
Hagen F, Khayhan K, Theelen B, et al. Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex. Fungal Genet Biol. 2015;78:16-48.
Gago S, Serrano C, Alastruey-Izquierdo A, et al. Molecular identification, antifungal resistance and virulence of Cryptococcus neoformans and Cryptococcus deneoformans isolated in Seville, Spain. Mycoses. 2017;60(1):40-50.
Ferrara G, Panizo MM, Urdaneta E, et al. Characterization by PCR-RFLP of the Cryptococcus neoformans and Cryptococcus gattii species complex in Venezuela. Investigación Clínica. 2018;59(1):28-40.
Trilles L, Lazéra MS, Wanke B, et al. Regional pattern of the molecular types of Cryptococcus neoformans and Cryptococcus gattii in Brazil. Mem Inst Oswaldo Cruz. 2008;103(5):455-462.
Santos D, Hagen F, Meis JF, et al. Donor-derived transmission of cryptococcus gattii sensu lato in kidney transplant recipients. Emerg Infect Dis. 2020;26(6):1329-1331.
Consenso em criptococose - 2008. Rev Soc Bras Med Trop. 2008;41:524-44.
WHO. Guidelines for the Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children: Supplement to the 2016. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Geneva, Switzerland: World Health Organization, 2018.
Trilles L, Meyer W, Wanke B, Guarro J, Lazéra M. Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex. Med Mycol. 2012;50(3):328-332.
Nascimento E, Vitali LH, Tonani L, Kress MR, Takayanagui OM, Martinez R. Refractory and/or Relapsing Cryptococcosis Associated with Acquired Immune Deficiency Syndrome: Clinical Features, Genotype, and Virulence Factors of Cryptococcus spp. Isolates. Am J Trop Med Hyg. 2016;94(5):975-981.
de Carvalho SR, Schiave LA, Dos Santos Quaglio AS, de Gaitani CM, Martinez R. Fluconazole Non-susceptible Cryptococcus neoformans, Relapsing/Refractory Cryptococcosis and Long-term Use of Liposomal Amphotericin B in an AIDS Patient. Mycopathologia. 2017;182(9-10):855-861.
Fan X, Xiao M, Chen S, et al. Predominance of Cryptococcus neoformans var. grubii multilocus sequence type 5 and emergence of isolates with non-wild-type minimum inhibitory concentrations to fluconazole: a multi-centre study in China. Clin Microbiol Infect. 2016;22(10):887.e1-887.e9.
Selb R, Fuchs V, Graf B, et al. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017. Int J Med Microbiol. 2019;309(6):151336.
Zaragoza O. Basic principles of the virulence of Cryptococcus. Virulence. 2019;10(1):490-501.
Mylonakis E. Galleria mellonella and the Study of Fungal Pathogenesis: Making the Case for Another Genetically Tractable Model Host. Mycopathologia. 2008;165:1-3.
Eisenman HC, Duong R, Chan H, Tsue R, McClelland EE. Reduced virulence of melanized Cryptococcus neoformans in Galleria mellonella. Virulence. 2014;5(5):6110618.
Paziani MH, Tonani L, de Menezes HD, et al. Antimicrobial photodynamic therapy with phenothiazinium photosensitizers in non-vertebrate model Galleria mellonella infected with Fusarium keratoplasticum and Fusarium moniliforme. Photodiagnosis Photodyn Ther. 2019;25:197-203.
Aoki FH, Imai T, Tanaka R, et al. New PCR primer pairs specific for Cryptococcus neoformans serotype A or B prepared on the basis of random amplified polymorphic DNA fingerprint pattern analyses. J Clin Microbiol. 1999;37(2):315-320.
Meyer W, Trilles L. Genotyping of the Cryptococcus neoformans/C. gattii species complex. Australian. Biochemist. 2010;41:12-15.
CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast (3th edn). CLSI standard M27. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
CLSI. Epidemiological Cutoff Values for Antifungal Susceptibility Testing, 2nd ed. Pennsylvania 19087 USA: CLSI supplement M59. Clinical and Laboratory Standards Institute, Wayne; 2018.
Zaragoza O, Fries BC, Casadevall A. Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO(2). Infect Immun. 2003;71(11):6155-6164.
Pedroso RS, Ferreira JC, Lavrador MAS, Maffei CML, Candido RC. Evaluation of the experimental inoculation of Cryptococcus albidus and Cryptococcus laurentii in normal mice: virulence factors and molecular profile before and after animal passage. Mycopathologia. 2009;168:59-72.
Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. Antimicrob Agents Chemother. 2012;56(6):3107-3113.
Espinel-Ingroff A, Aller AI, Canton E, et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother. 2012;56(11):5898-5906.
Matos CS, de Souza AA, Oliveira NS, Barros TF. Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities. Eur J Clin Microbiol Infect Dis. 2012;31(7):1647-1652.
Cattana ME, Tracogna MF, Fernández MS, Carol Rey MC, Sosa MA, Giusiano GE.Genotipificación de aislamientos clínicos del complejo Cryptococcus neoformans/Cryptococcus gattii obtenidos en el Hospital «Dr. Julio C. Perrando», de la ciudad de Resistencia (Chaco, Argentina) [Genotyping of Cryptococcus neoformans/Cryptococcus gattii complex clinical isolates from Hospital "Dr. Julio C. Perrando", Resistencia city (Chaco, Argentina)]. Rev Argent Microbiol. 2013;45(2):89-92.
Silva DC, Martins MA, Szeszs MW, Bonfietti LX, Matos D, Melhem MS. Susceptibility to antifungal agents and genotypes of Brazilian clinical and environmental Cryptococcus gattii strains. Diagn Microbiol Infect Dis. 2012;72(4):332-339.
Herkert PF, Hagen F, de Oliveira Salvador GL, et al. Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil. Eur J Clin Microbiol Infect Dis. 2016;35(11):1803-1810.
Herkert PF, Meis JF, de Oliveira L, et al. Molecular characterization and antifungal susceptibility testing of Cryptococcus neoformans sensu stricto from southern Brazil. J Med Microbiol. 2018;67(4):560-569.
Pharkjaksu S, Chongtrakool P, Chayakulkeeree M, et al. Cryptococcus neoformans/gattii Species Complexes from Pre-HIV Pandemic Era Contain Unusually High Rate of Non-Wild-Type Isolates for Amphotericin B. Infect Drug Resist. 2020;13:673-681.
Nascimento E, Vitali LH, Kress MRVZ, Martinez R. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease. Rev Inst Med Trop Sao Paulo. 2017;59:49.
Bandalizadeh Z, Shokohi T, Badali H, et al. Molecular epidemiology and antifungal susceptibility profiles of clinical Cryptococcus neoformans/Cryptococcus gattii species complex. J Med Microbiol. 2020;69(1):72-81.
Hospenthal DR, Bennett JE. Flucytosine monotherapy for cryptococcosis. Clin Infect Dis. 1998;27(2):260-264.
Loyse A, Dromer F, Day J, Lortholary O, Harrison TS. Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. J Antimicrob Chemother. 2013;68(11):2435-2444.
Hagen F, Hare Jensen R, Meis JF, Arendrup MC. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark. Mycoses. 2016;59(9):576-584.
Herkert PF, Hagen F, Pinheiro RL, Muro MD, Meis JF, Queiroz-Telles F. Ecoepidemiology of Cryptococcus gattii in Developing Countries. J Fungi (Basel). 2017;3(4):62.
Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23(4):525-530.
May RC, Stone NR, Wiesner DL, Bicanic T, Nielsen K. Cryptococcus: from environmental saprophyte to global pathogen. Nat Rev Microbiol. 2016;14(2):106-117.
Perfect JR, Bicanic T. Cryptococcosis diagnosis and treatment: What do we know now. Fungal Genet Biol. 2015;78:49-54.
Desnos-Ollivier M, Patel S, Raoux-Barbot D, Heitman J, Dromer F, French Cryptococcosis Study Group. Cryptococcosis Serotypes Impact Outcome and Provide Evidence of Cryptococcus neoformans Speciation. MBio. 2015;6(3):e00311.
Spina-Tensini T, Muro MD, Queiroz-Telles F, et al. Geographic distribution of patients affected by Cryptococcus neoformans/Cryptococcus gattii species complexes meningitis, pigeon and tree populations in Southern Brazil. Mycoses. 2017;60(1):51-58.
Bauer M, Wickenhauser C, Haak A, et al. Case report: A fatal case of cryptococcosis in an immunocompetent patient due to Cryptococcus deuterogattii (AFLP6/VGII). JMM case reports. 2018;5(10):e005168.
Bollam R, Yassin M, Phan T. Disseminated cryptococcosis in an immunocompetent patient. Respir Med Case Rep. 2020;30:101034.
Nascimento E, Bonifácio da Silva ME, Martinez R, von Zeska Kress MR. Primary cutaneous cryptococcosis in an immunocompetent patient due to Cryptococcus gattii molecular type VGI in Brazil: a case report and review of literature. Mycoses. 2014;57(7):442-447.
Litvintseva AP, Mitchell TG. Most environmental isolates of Cryptococcus neoformans var. grubii (serotype A) are not lethal for mice. Infect Immun. 2009;77:3188-3195.
Mukaremera L, McDonald TR, Nielsen JN, et al. The mouse inhalation model of Cryptococcus neoformans infection recapitulates strain virulence in humans and shows that closely related strains can possess differential virulence. Infect Immun. 2019;87:e00046-e119.